{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:46:03Z","timestamp":1792673163547,"version":"4.5.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bio&Medical Technology Development Program of the National Research Foundation"},{"name":"Korean government","award":["RS-2024-00440371"],"award-info":[{"award-number":["RS-2024-00440371"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study was to explore how serum ghrelin levels modulate the relationship between interleukin-6 (IL-6) and outcomes of antidepressant treatment, specifically focusing on 12-week remission and 24-month relapse in patients with depressive disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This investigation involved the analysis of baseline serum levels of ghrelin and IL-6 among 1086 patients enrolled in a naturalistic study of stepwise antidepressant therapy. Remission was determined by a Hamilton Depression Rating Scale (HAMD) score of 7 or less at 12\u00a0weeks. Those who responded (HAMD score\u2009\u2009&amp;lt;14) at this juncture were subsequently monitored for relapse (HAMD score\u2009\u2009\u226514) quarterly over a 24-month period. The study employed logistic regression models, adjusted for various sociodemographic and clinical factors, to evaluate the interaction between these biomarkers and treatment outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Findings revealed that while serum ghrelin levels did not independently affect treatment outcomes, they significantly influenced the association between elevated IL-6 levels and the risks of non-remission at 12\u00a0weeks and relapse at 24\u00a0months. Specifically, high IL-6 levels correlated with poorer outcomes predominantly in the presence of lower ghrelin levels, with these interactions reaching statistical significance in relapse outcomes post-adjustment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The study highlights the complex interplay between IL-6 and ghrelin in shaping the efficacy of antidepressant treatments, demonstrating divergent influences on remission and relapse. These results emphasize the importance of incorporating multiple biomarkers into predictive models to tailor antidepressant strategies more effectively. Continued research is needed to dissect the underlying dynamics of these biomarker interactions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ijnp\/pyag032","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:43:07Z","timestamp":1781782987000},"source":"Crossref","is-referenced-by-count":0,"title":["Divergent effects of interleukin-6 and ghrelin on remission and relapse in depression treatment"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7409-6306","authenticated-orcid":false,"given":"Jae-Min","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Chonnam National University Medical School , Gwangju ,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee-Ju","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Chonnam National University Medical School , Gwangju ,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Wan","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Chonnam National University Medical School , Gwangju ,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Jhon","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Chonnam National University Medical School , Gwangju ,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Yeon","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Chonnam National University Medical School , Gwangju ,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6739-2163","authenticated-orcid":false,"given":"Sung-Wan","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Chonnam National University Medical School , Gwangju ,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Il-Seon","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Chonnam National University Medical School , Gwangju ,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"2026102208021263700_ref1","doi-asserted-by":"publisher","first-page":"12346","DOI":"10.1038\/s41598-024-62381-9","article-title":"Temporal and spatial trend analysis of all-cause depression burden based on global burden of disease (GBD) 2019 study","volume":"14","author":"Liu","year":"2024","journal-title":"Sci Rep"},{"key":"2026102208021263700_ref2","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1017\/S0033291721004943","article-title":"Clinical research challenges posed by difficult-to-treat depression","volume":"52","author":"Rush","year":"2022","journal-title":"Psychol Med"},{"key":"2026102208021263700_ref3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am J Psychiatry"},{"key":"2026102208021263700_ref4","volume-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR","author":"American Psychiatric Association","year":"2000"},{"key":"2026102208021263700_ref5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jad.2017.07.001","article-title":"Peripheral biomarkers of major depression and antidepressant treatment response: current knowledge and future outlooks","volume":"233","author":"Gadad","year":"2018","journal-title":"J Affect Disord"},{"key":"2026102208021263700_ref6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nri.2015.5","article-title":"The role of inflammation in depression: from evolutionary imperative to modern treatment target","volume":"16","author":"Miller","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"2026102208021263700_ref7","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.biopsych.2009.09.033","article-title":"A meta-analysis of cytokines in major depression","volume":"67","author":"Dowlati","year":"2010","journal-title":"Biol Psychiatry"},{"key":"2026102208021263700_ref8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1017\/neu.2017.2","article-title":"Adjunctive N-acetylcysteine in depression: exploration of interleukin-6, C-reactive protein and brain-derived neurotrophic factor","volume":"29","author":"Hasebe","year":"2017","journal-title":"Acta Neuropsychiatr"},{"key":"2026102208021263700_ref9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.psyneuen.2016.11.031","article-title":"Oxidative stress, inflammation and treatment response in major depression","volume":"76","author":"Lindqvist","year":"2017","journal-title":"Psychoneuroendocrinology"},{"key":"2026102208021263700_ref10","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/hup.717","article-title":"IL-6 levels decrease with SSRI treatment in patients with major depression","volume":"20","author":"Basterzi","year":"2005","journal-title":"Hum Psychopharmacol"},{"key":"2026102208021263700_ref11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41380-019-0474-5","article-title":"Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis","volume":"25","author":"Liu","year":"2020","journal-title":"Mol Psychiatry"},{"key":"2026102208021263700_ref12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jad.2014.03.023","article-title":"C-reactive protein, interleukin-6, soluble tumor necrosis factor \u03b1 receptor 2 and incident clinical depression","volume":"163","author":"Chocano-Bedoya","year":"2014","journal-title":"J Affect Disord"},{"key":"2026102208021263700_ref13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jad.2017.07.016","article-title":"(2017) partially distinct combinations of psychological, metabolic and inflammatory risk factors are pro spectively associated with the onset of the subtypes of major depressive disorder in midlife","volume":"222","author":"Rudaz","year":"2017","journal-title":"J Affect Disord"},{"key":"2026102208021263700_ref14","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1017\/S0033291717002744","article-title":"Mood disorders and circulating levels of inflammatory markers in a longitudinal population-based study","volume":"48","author":"Glaus","year":"2018","journal-title":"Psychol Med"},{"key":"2026102208021263700_ref15","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1001\/jamapsychiatry.2014.1332","article-title":"Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study","volume":"71","author":"Khandaker","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"2026102208021263700_ref16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ynstr.2016.03.003","article-title":"Integrating Interleukin-6 into depression diagnosis and treatment","volume":"4","author":"Hodes","year":"2016","journal-title":"Neurobiol Stress"},{"key":"2026102208021263700_ref17","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.biopsych.2012.03.010","article-title":"Ghrelin regulates the hypothalamic-pituitary-adrenal axis and restricts anxiety after acute stress","volume":"72","author":"Spencer","year":"2012","journal-title":"Biol Psychiatry"},{"key":"2026102208021263700_ref18","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.mehy.2006.12.042","article-title":"Ghrelin may attenuate proinflammatory cytokine-mediated neuropathic pain","volume":"69","author":"Guneli","year":"2007","journal-title":"Med Hypotheses"},{"key":"2026102208021263700_ref19","first-page":"367","article-title":"Plasma ghrelin and interleukin-6 levels correlate with body mass index and arterial blood pressure in males with essential hypertension","volume":"66","author":"Gibas-Dorna","year":"2015","journal-title":"J Physiol Pharmacol"},{"key":"2026102208021263700_ref20","doi-asserted-by":"publisher","first-page":"e22508","DOI":"10.1096\/fj.202200634R","article-title":"Potential role of ghrelin in the regulation of inflammation","volume":"36","author":"Ma","year":"2022","journal-title":"FASEB J"},{"key":"2026102208021263700_ref21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1172\/JCI21134","article-title":"Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells","volume":"114","author":"Dixit","year":"2004","journal-title":"J Clin Invest"},{"key":"2026102208021263700_ref22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00395-018-0671-4","article-title":"Cardioprotective effect of ghrelin against myocardial infarction-induced left ventricular injury via inhibition of SOCS3 and activation of JAK2\/STAT3 signaling","volume":"113","author":"Eid","year":"2018","journal-title":"Basic Res Cardiol"},{"key":"2026102208021263700_ref23","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1172\/JCI57660","article-title":"Ghrelin mediates stress-induced food-reward behavior in mice","volume":"121","author":"Chuang","year":"2011","journal-title":"J Clin Invest"},{"key":"2026102208021263700_ref24","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/nn.2139","article-title":"The orexigenic hormone ghrelin defends against depressive symptoms of chronic stress","volume":"11","author":"Lutter","year":"2008","journal-title":"Nat Neurosci"},{"key":"2026102208021263700_ref25","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.3390\/nu15183960","article-title":"Ghrelin as a biomarker of \u201cImmunometabolic depression\u201d and its connection with dysbiosis","volume":"15","author":"Gajewska","year":"2023","journal-title":"Nutrients"},{"key":"2026102208021263700_ref26","doi-asserted-by":"publisher","first-page":"538","DOI":"10.30773\/pi.2017.10.2","article-title":"The MAKE biomarker discovery for enhancing anTidepressant treatment effect and response (MAKE BETTER) study: design and methodology","volume":"15","author":"Kang","year":"2018","journal-title":"Psychiatry Investig"},{"key":"2026102208021263700_ref27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.bbi.2021.01.029","article-title":"Interactive effects of systemic inflammation and life stressors on treatment response of depressive disorders","volume":"95","author":"Choi","year":"2021","journal-title":"Brain Behav Immun"},{"key":"2026102208021263700_ref28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.bbi.2022.05.012","article-title":"Prospective associations of multimodal serum biomarkers with 12-week and 12-month remission in patients with depressive disorders receiving stepwise psychopharmacotherapy","volume":"104","author":"Kim","year":"2022","journal-title":"Brain Behav Immun"},{"key":"2026102208021263700_ref29","doi-asserted-by":"publisher","first-page":"115198","DOI":"10.1016\/j.psychres.2023.115198","article-title":"Age-specific associations between inflammatory markers and remission of depression during antidepressant use","volume":"324","author":"Kim","year":"2023","journal-title":"Psychiatry Res"},{"key":"2026102208021263700_ref30","doi-asserted-by":"publisher","first-page":"197","DOI":"10.5127\/jep.008310","article-title":"Best practices for using median splits, artificial categorization, and their continuous alternatives","volume":"2","author":"DeCoster","year":"2009","journal-title":"J Exp Psychopathol"},{"key":"2026102208021263700_ref31","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"key":"2026102208021263700_ref32","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994","edition":"4"},{"key":"2026102208021263700_ref33","doi-asserted-by":"publisher","first-page":"423","DOI":"10.15288\/jsa.1995.56.423","article-title":"The alcohol use disorders identification test (AUDIT): validation of a screening instrument for use in medical settings","volume":"56","author":"Bohn","year":"1995","journal-title":"J Stud Alcohol"},{"key":"2026102208021263700_ref34","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jad.2020.05.002","article-title":"Short and long-term treatment outcomes of stepwise psychopharmacotherapy based on early clinical decision in patients with depressive disorders","volume":"274","author":"Kim","year":"2020","journal-title":"J Affect Disord"},{"key":"2026102208021263700_ref35","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026102208021263700_ref36","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1001\/archpsyc.55.4.334","article-title":"Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo","volume":"55","author":"Stewart","year":"1998","journal-title":"Arch Gen Psychiatry"},{"key":"2026102208021263700_ref37","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am J Psychiatry"},{"key":"2026102208021263700_ref38","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11011-008-9118-1","article-title":"The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression","volume":"24","author":"Maes","year":"2009","journal-title":"Metab Brain Dis"},{"key":"2026102208021263700_ref39","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41380-019-0585-z","article-title":"Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis","volume":"25","author":"Kennis","year":"2020","journal-title":"Mol Psychiatry"},{"key":"2026102208021263700_ref40","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.molmet.2015.03.005","article-title":"Ghrelin","volume":"4","author":"M\u00fcller","year":"2015","journal-title":"Mol Metab"},{"key":"2026102208021263700_ref41","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jad.2013.01.014","article-title":"A review of lifestyle factors that contribute to important pathways associated with major depression: diet, sleep and exercise","volume":"148","author":"Lopresti","year":"2013","journal-title":"J Affect Disord"},{"key":"2026102208021263700_ref42","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.bbi.2016.03.025","article-title":"Inflammatory markers are associated with decreased psychomotor speed in patients with major depressive disorder","volume":"56","author":"Goldsmith","year":"2016","journal-title":"Brain Behav Immun"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyag032\/68568181\/pyag032.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/29\/10\/pyag032\/68568181\/pyag032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/29\/10\/pyag032\/68568181\/pyag032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:02:18Z","timestamp":1792670538000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/doi\/10.1093\/ijnp\/pyag032\/8712861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyag032","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,6,22]]},"article-number":"pyag032"}}